Each year millions of people die from cancer worldwide. The World Health Organization (WHO) has estimated that the number of people dying from cancer will increase from 7.6 million in 2008 to more than 13.1 million by 2030*.
High throughput sequencing gives access to a wealth of information that makes it possible to uncover cancer specific disruptions in gene expression, methylation, histone modification patterns, and other regulatory mechanisms. Whole genome-, exon-, and RNA- sequencing are some of the techniques used to identify inherited disease traits, damaging polymorphisms, structural variations, and somatic mutations that underlie this complex disease.
Being the world’s leading bioinformatics solution provider, CLC bio develops bioinformatics software for cutting edge science in close collaboration with researchers and clinicians worldwide.
We have launched this site to help researchers and clinicians in their effort to reduce the number of cancer deaths. Personalized medicine, based on each individual patient’s unique genetic and epigenetic profile, is one approach. Other approaches are identification of novel drug targets and biomarkers for early detection of cancer.
More informationThe challenge of treating cancer
*Reference: World Health Organization (http://www.who.int/mediacentre/factsheets/fs297/en/index.html )